Department of Cardiology, Faculty of Medicine, Gazi University; Ankara-Turkey.
Department of Cardiology, Faculty of Medicine, Pamukkale University; Denizli-Turkey.
Anatol J Cardiol. 2021 Nov;25(11):789-795. doi: 10.5152/AnatolJCardiol.2021.03982.
To evaluate the prognostic value of preprocedural CHA2DS2-VASc [congestive heart failure, hypertension, age ≥75 years (doubled), diabetes mellitus, previous stroke or transient ischemic attack (TIA) (doubled), vascular disease, age 65-74 years, female gender] score in predicting high SYNTAX (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) score and in-hospital mortality for non-atrial fibrillation (AF) patients presenting with non-ST elevation myocardial infarction (NSTEMI). The CHA2DS2-VASc score used to determine thromboembolic risks in AF was recently reported to predict major adverse clinical outcomes in patients with the acute coronary syndrome, irrespective of AF.
A total of 906 patients with a diagnosis of NSTEMI who underwent coronary angiography were retrospectively enrolled and divided into three groups according to their SYNTAX scores (low, intermediate, and high). The CHA2DS2-VASc score of each patient was calculated.
SYNTAX score had a significant positive correlation with the CHA2DS2-VASc score (r=0.320; p<0.001) in the Spearman correlation analysis. The CHA2DS2-VASc score [Odds ratio, 1.445; 95% confidence interval (CI), 1.268-1.648, p<0.001], left ventricular ejection fraction, creatinine, C-reactive protein, and high-density and low-density lipoprotein cholesterol levels were demonstrated to be independent predictors of high SYNTAX score. The CHA2DS2-VASc score [Hazard ratio (HR), 1.867; 95% CI: 1.462-2.384; p<0.001], the SYNTAX score (HR, 1.049; p=0.003), and age (HR, 1.057; p=0.002) were independently associated with higher risk of in-hospital mortality in a multiple Cox-regression model. Kaplan-Meier survival curves stratified by the CHA2DS2-VASc score (<4 vs. ≥4) also showed that higher CHA2DS2-VASc scores were associated with higher in-hospital mortality.
In non-AF patients with NSTEMI, CHA2DS2-VASc and SYNTAX scores are useful for prognosis assessment and can be used to identify patients at higher risk for in-hospital mortality.
评估术前 CHA2DS2-VASc [充血性心力衰竭、高血压、年龄≥75 岁(加倍)、糖尿病、既往卒中或短暂性脑缺血发作(TIA)(加倍)、血管疾病、65-74 岁、女性]评分对预测非心房颤动(AF)患者非 ST 段抬高型心肌梗死(NSTEMI)患者高 SYNTAX(经皮冠状动脉介入治疗与 Taxus 和心脏手术的协同作用)评分和院内死亡率的预后价值。最近有报道称,用于确定 AF 中血栓栓塞风险的 CHA2DS2-VASc 评分可预测急性冠状动脉综合征患者的主要不良临床结局,无论 AF 患者是否存在。
回顾性纳入 906 例经冠状动脉造影诊断为 NSTEMI 的患者,并根据 SYNTAX 评分(低、中、高)将其分为三组。计算每位患者的 CHA2DS2-VASc 评分。
Spearman 相关分析显示,SYNTAX 评分与 CHA2DS2-VASc 评分呈显著正相关(r=0.320;p<0.001)。CHA2DS2-VASc 评分[比值比,1.445;95%置信区间(CI),1.268-1.648,p<0.001]、左心室射血分数、肌酐、C 反应蛋白以及高密度脂蛋白和低密度脂蛋白胆固醇水平被证明是高 SYNTAX 评分的独立预测因素。CHA2DS2-VASc 评分[风险比(HR),1.867;95%CI:1.462-2.384;p<0.001]、SYNTAX 评分(HR,1.049;p=0.003)和年龄(HR,1.057;p=0.002)与多 Cox 回归模型中更高的院内死亡率风险独立相关。根据 CHA2DS2-VASc 评分(<4 与≥4)分层的 Kaplan-Meier 生存曲线也表明,较高的 CHA2DS2-VASc 评分与更高的院内死亡率相关。
在非 AF 伴 NSTEMI 的患者中,CHA2DS2-VASc 和 SYNTAX 评分可用于预后评估,并可用于识别院内死亡率较高的患者。